7-chloro-9-ethyl-6-hydroxyisoxazolo[3,4-b]quinoline-3,4(1H,9H)-dione | 1082203-91-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 7-chloro-9-ethyl-6-hydroxyisoxazolo[3,4-b]quinoline-3,4(1H,9H)-dione
• 英文别名: 7-chloro-9-ethyl-6-hydroxy-1H,3H,4H,9H-quinolino[2,3-c][1,2]oxazole-3,4-dione；7-chloro-9-ethyl-6-hydroxy-1H-[1,2]oxazolo[3,4-b]quinoline-3,4-dione
• CAS: 1082203-91-5
• 化学式: C₁₂H₉ClN₂O₄
• 分子量: 280.667
• InChiKey: HNODKCFEFLQKBO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  78.9
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  7-chloro-9-ethyl-6-methoxy-1H,3H,4H,9H-quinolino[2,3-c][1,2]oxazole-3,4-dione 在 aluminum (III) chloride 作用下， 以 甲苯 为溶剂， 以43%的产率得到7-chloro-9-ethyl-6-hydroxyisoxazolo[3,4-b]quinoline-3,4(1H,9H)-dione
  参考文献：
  名称：

  Isoxazolo[3,4-b]quinoline-3,4(1H,9H)-diones as unique, potent and selective inhibitors for Pim-1 and Pim-2 kinases: Chemistry, biological activities, and molecular modeling

  摘要：

  A series of isoxazolo[3,4-b]quinoline-3,4(1H,9H)-diones were synthesized as potent inhibitors against Pim-1 and Pim-2 kinases. The structure-activity-relationship studies started from a high-throughput screening hit and was guided by molecular modeling of inhibitors in the active site of Pim-1 kinase. Installing a hydroxyl group on the benzene ring of the core has the potential to form a key hydrogen bond interaction to the hinge region of the binding pocket and thus resulted in the most potent inhibitor, 19, with K-i values at 2.5 and 43.5 nM against Pim-1 and Pim-2, respectively. Compound 19 also exhibited an activity pro. le with a high degree of kinase selectivity. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.08.079

文献信息

• PIM kinase inhibitors in combination with RNA splicing modulators/inhibitors for treatment of cancers
  申请人：UNIVERSITY OF MARYLAND, BALTIMORE COUNTY

  公开号：US10842785B2

  公开（公告）日：2020-11-24

  The present invention provides for a method of treating cancer and/or reducing proliferation of cancer cells, the method comprising administering to a subject in need of such treatment a composition comprising a PIM kinase inhibitor that exhibits changes of mRNA splicing in combination with a compound that modulates/inhibits activity of an RNA splicing factor protein. Further, changes in splicing of mRNAs and phosphorylation of RNA splicing factors can be used as biomarkers for patient responsiveness to anti-PIM treatment and also suggest effective combinatorial therapies, including synergistic combination.

  本发明提供了一种治疗癌症和/或减少癌细胞增殖的方法，该方法包括向需要这种治疗的受试者施用一种组合物，该组合物包含一种PIM激酶抑制剂，该PIM激酶抑制剂与一种调节/抑制RNA剪接因子蛋白活性的化合物相结合，可显示出mRNA剪接的变化。此外，mRNA 的剪接变化和 RNA 剪接因子的磷酸化可用作患者对抗 PIM 治疗反应性的生物标志物，还可提示有效的组合疗法，包括协同组合疗法。
• PIM kinase inhibitors in combination with autophagy inhibitors for treatment of cancers
  申请人：UNIVERSITY OF MARYLAND, BALTIMORE COUNTY

  公开号：US11389440B2

  公开（公告）日：2022-07-19

  The present invention provides for a method of treating cancer and/or reducing proliferation of cancer cells, the method comprising administering to a subject in need of such treatment a composition comprising a PIM kinase inhibitor that exhibits changes in expressed RNA or ribosomal binding proteins in combination with a compound that inhibits autophagy.

  本发明提供了一种治疗癌症和/或减少癌细胞增殖的方法，该方法包括向需要这种治疗的受试者施用一种组合物，该组合物包含一种 PIM 激酶抑制剂，该抑制剂与一种抑制自噬的化合物结合使用，后者在表达的 RNA 或核糖体结合蛋白中显示出变化。
• PEPTIDE EPOXYKETONE PROTEASOME INHIBITORS IN COMBINATION WITH PIM KINASE INHIBITORS FOR TREATMENT OF CANCERS
  申请人：Onyx Therapeutics, Inc.

  公开号：EP3021862A2

  公开（公告）日：2016-05-25
• PIM KINASE INHIBITORS IN COMBINATION WITH RNA SPLICING MODULATORS/INHIBITORS FOR TREATMENT OF CANCERS
  申请人：University of Maryland, Baltimore County

  公开号：EP3432886B1

  公开（公告）日：2021-06-02
• PIM KINASE INHIBITORS IN COMBINATION WITH AUTOPHAGY INHIBITORS FOR TREATMENT OF CANCERS
  申请人：UNIVERSITY OF MARYLAND, BALTIMORE COUNTY

  公开号：US20200230125A1

  公开（公告）日：2020-07-23

  The present invention provides for a method of treating cancer and/or reducing proliferation of cancer cells, the method comprising administering to a subject in need of such treatment a composition comprising a PIM kinase inhibitor that exhibits changes in expressed RNA or ribosomal binding proteins in combination with a compound that inhibits autophagy.